JP2018502080A5 - - Google Patents

Download PDF

Info

Publication number
JP2018502080A5
JP2018502080A5 JP2017533387A JP2017533387A JP2018502080A5 JP 2018502080 A5 JP2018502080 A5 JP 2018502080A5 JP 2017533387 A JP2017533387 A JP 2017533387A JP 2017533387 A JP2017533387 A JP 2017533387A JP 2018502080 A5 JP2018502080 A5 JP 2018502080A5
Authority
JP
Japan
Prior art keywords
dengue
vaccine
composition
live
serotype
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017533387A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018502080A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/066549 external-priority patent/WO2016106107A2/en
Publication of JP2018502080A publication Critical patent/JP2018502080A/ja
Publication of JP2018502080A5 publication Critical patent/JP2018502080A5/ja
Pending legal-status Critical Current

Links

JP2017533387A 2014-12-22 2015-12-18 デングウイルスワクチン組成物およびその使用方法 Pending JP2018502080A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462095331P 2014-12-22 2014-12-22
US62/095,331 2014-12-22
PCT/US2015/066549 WO2016106107A2 (en) 2014-12-22 2015-12-18 Dengue virus vaccine compositions and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2018502080A JP2018502080A (ja) 2018-01-25
JP2018502080A5 true JP2018502080A5 (https=) 2019-01-31

Family

ID=56151628

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017533387A Pending JP2018502080A (ja) 2014-12-22 2015-12-18 デングウイルスワクチン組成物およびその使用方法

Country Status (16)

Country Link
US (1) US10449243B2 (https=)
EP (1) EP3236997B1 (https=)
JP (1) JP2018502080A (https=)
CN (1) CN106999568A (https=)
AU (1) AU2015369875A1 (https=)
BR (1) BR112017013270A2 (https=)
CL (1) CL2017001595A1 (https=)
CO (1) CO2017005830A2 (https=)
CR (1) CR20170280A (https=)
ES (1) ES2981476T3 (https=)
MX (1) MX383329B (https=)
MY (1) MY192543A (https=)
NI (1) NI201700080A (https=)
PH (1) PH12017501165B1 (https=)
SG (1) SG11201704942QA (https=)
WO (1) WO2016106107A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170143817A1 (en) * 2015-11-20 2017-05-25 Oregon Health & Science University Dengue virus vaccine
TWI625393B (zh) * 2016-11-15 2018-06-01 國立清華大學 對抗複數種登革熱病毒血清型之疫苗套組及其製備方法與用途
WO2019112921A1 (en) 2017-12-07 2019-06-13 Merck Sharp & Dohme Corp. Formulations of dengue virus vaccine compositions
WO2020236973A1 (en) * 2019-05-20 2020-11-26 Soligenix, Inc. Compositions and methods of manufacturing trivalent filovirus vaccines
WO2025027616A1 (en) * 2023-08-01 2025-02-06 Serum Institute Of India Private Limited Freeze-dried viral vaccine compositions and method of manufacturing thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184024B1 (en) * 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
US6190859B1 (en) 1995-04-17 2001-02-20 The United States Of America As Represented By The Secretary Of The Army Method and kit for detection of dengue virus
US6254873B1 (en) 1995-04-17 2001-07-03 The United States Of America As Represented By The Secretary Of The Army Inactivated dengue virus vaccine
WO1996040933A1 (en) 1995-06-07 1996-12-19 The Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services Infectious dengue 2 virus pdk-53 as quadravalent vaccine
EP0836090A1 (en) 1996-10-12 1998-04-15 Evotec BioSystems GmbH Method of analysis of samples by determination of the distribution of specific brightnesses of particles
EP0977587B1 (en) 1997-02-28 2005-06-15 Acambis Inc. Chimeric flavivirus vaccines
WO1999006068A2 (en) 1997-07-31 1999-02-11 Hawaii Biotechnology Group, Inc. Recombinant dimeric envelope vaccine against flaviviral infection
AU774045B2 (en) 1998-09-02 2004-06-17 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Dengue viruses that are replication defective in mosquitos for use as vaccines
EP1165127B1 (en) 1999-03-26 2008-12-31 Walter Reed Army Institute of Research Multivalent dengue virus vaccine
US6537557B1 (en) 1999-03-26 2003-03-25 The United States Of America As Represented By The Secretary Of The Army Attenuated dengue-4 virus vaccine
WO2000057909A2 (en) 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Attenuated dengue-2 virus vaccine
JP2002540169A (ja) 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ 弱毒化デング熱1型ウイルスワクチン
US6432411B1 (en) 1999-07-13 2002-08-13 Hawaii Biotechnology Group Recombinant envelope vaccine against flavivirus infection
CA2966716C (en) 2001-05-22 2019-11-26 The Government Of The United States Of America, As Represented By The Cretary, Department Of Health And Human Services Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
KR101074175B1 (ko) 2002-01-15 2011-10-14 사노피 파스테르 바이오로직스 씨오 플라비바이러스 백신
ATE481982T1 (de) 2002-05-03 2010-10-15 Us Gov Health & Human Serv Dengue-vakzine mit einer gemeinsamen 30 nukleotid-deletion im 3'-utr der dengue-typen 1 und 2.
US20040259224A1 (en) 2002-05-31 2004-12-23 Farshad Guirakhoo Tetravalent Dengue vaccines
US7189403B2 (en) 2003-06-30 2007-03-13 Institut Pasteur Attenuated flavivirus strains containing a mutated M-ectodomain and their applications
CA2549173A1 (en) 2003-12-08 2005-07-07 Hybridon, Inc. Modulation of immunostimulatory properties by small oligonucleotide-based compounds
SG156666A1 (en) 2004-10-20 2009-11-26 Acambis Inc Vaccines against japanese encephalitis virus and west nile virus
CA2611954C (en) 2005-06-17 2014-01-28 Sanofi Pasteur Dengue serotype 2 attenuated strain
CN101238144B (zh) 2005-06-17 2012-09-05 赛诺菲巴斯德有限公司 登革血清型1减毒株
CA2612047C (en) 2005-06-24 2015-05-12 Intervet International B.V. Inactivated chimeric vaccines and related methods of use
CA2616026A1 (en) 2005-07-22 2007-02-08 Research Development Foundation Attenuated strains of flaviviruses , and uses thereof
US7470674B2 (en) 2005-11-07 2008-12-30 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
AR061197A1 (es) 2006-06-07 2008-08-13 Sanofi Pasteur Cepas del virus 3 del dengue vivas atenuadas
PL2589602T3 (pl) * 2006-08-15 2016-11-30 Rozwinięcie komponentów szczepionki przeciwko wirusowi dengi
FR2906724B1 (fr) 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
ES2517615T3 (es) 2006-11-09 2014-11-03 The United States Of America As Represented By The Secretary Of The Navy Inducción de una respuesta inmunitaria frente al virus del dengue usando un enfoque de sensibilización-refuerzo
US8440202B2 (en) 2006-11-09 2013-05-14 The United States Of America As Represented By The Secretary Of The Navy Induction of an immune response against dengue virus using the prime-boost approach
BRPI0904020B8 (pt) * 2009-10-01 2021-05-25 Fundacao Oswaldo Cruz composição vacinal contra o vírus da dengue, e, kit
AU2011367817B2 (en) * 2010-10-29 2015-05-28 Merck Sharp & Dohme Corp. Recombinant subunit dengue virus vaccine
WO2012065105A2 (en) * 2010-11-12 2012-05-18 Thomas Monath Chimeric flavivirus vaccines
AU2013295016A1 (en) * 2012-07-24 2015-01-29 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
JP2016523251A (ja) * 2013-06-21 2016-08-08 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. デングウイルスワクチン組成物およびその使用方法

Similar Documents

Publication Publication Date Title
JP2013542224A5 (https=)
US11883480B2 (en) Formulations of dengue virus vaccine compositions
JP2018502080A5 (https=)
TWI812650B (zh) 包含特別是減毒活重組黃病毒的穩定疫苗組成物以及製備其的製程
RU2541784C2 (ru) Лиофилизированная композиция для индукции иммунного ответа на флавивирус, композиция и способ для ее получения
Lai et al. Human Ebola virus infection in West Africa: a review of available therapeutic agents that target different steps of the life cycle of Ebola virus
JP2015535302A (ja) ビリオン分解に影響を及ぼすフラビウイルスのエンベロープタンパク質変異
JP2019511221A5 (https=)
JP2019511221A (ja) 弱毒化された生ジカウイルスワクチン
US9861692B2 (en) Dengue virus vaccine compositions and methods of use thereof
JP2016504315A5 (https=)
JP2019509750A (ja) 生弱毒化アルファウイルス構築物及び方法、ならびにそれらの使用
ES2981476T3 (es) Composiciones de vacunas contra el virus del dengue y métodos de uso de las mismas
US20140205624A1 (en) Tetravalent and mixed head bivalent dengue vaccine
WO2018129160A1 (en) Live attenuated flavivirus vaccines and methods of using and making same
CN108135995A (zh) 稳定的活的减毒重组登革疫苗
Simasathein et al. Dengue vaccine
BETTER IN MY VIEW, THE COVID-19 PANDEMIC
Park et al. Strategy for novel vaccine and antivirals against foot-and-mouth disease